ReviewFrontiers in immunology2026
Neoadjuvant therapy for hepatocellular carcinoma: emerging combinations and biomarker challenges.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally, with high recurrence rates limiting the success of curative treatments. Neoadjuvant therapy has recently arisen as a promising strategy to enhance surgical outcomes and survival. This review focuses specifically on neoadjuvant therapy for resectable HCC. Main findings: We summarize current neoadjuvant approaches in this defined setting, focusing on systemic therapies-including targeted agents, immune checkpoint inhibitors, and their combinations-as well as locoregional modalities such as transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), ablation, and radiotherapy. Systemic-locoregional combinations have demonstrated improved pathological response rates and event-free survival, with phase 2/3 trials such as CARES-009 providing the highest level of evidence to date. We further summarize progress in biomarkers for predicting treatment efficacy across molecular, cellular, histopathological, and imaging dimensions. Key advances include baseline immune activation signatures, dynamic serum biomarkers such as alpha-fetoprotein (AFP) kinetics and liquid biopsy indicators, and emerging radiomic signatures and spatial multi-omics approaches. We also highlight ongoing clinical trials that are evaluating novel combination regimens and biomarker-driven patient stratification. Conclusions: By identifying critical challenges in standardizing pathological response criteria, optimizing treatment duration and sequencing, and validating multimodal biomarkers, this review emphasizes the pivotal role of neoadjuvant therapy in reshaping curative-intent management for HCC and delineates actionable directions for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.